Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Melanoma | Meet The Professor: Optimizing the Management of Melanoma Sep 12, 2023

Show notes

Featuring perspectives from Prof Georgina Long, including the following topics:

Introduction: (0:00)
Journal Club with Prof Long – Part 1 (7:56)
Case: A man in his mid 70s presents with bilateral painfully inflamed red ears and is diagnosed with BRAF V600E-mutated metastatic melanoma — Joanna Metzner-Sadurski, MD (27:19)
Case: A man in his early 70s with past medical history of diabetes, hypertension, chronic obstructive pulmonary disease and several skin cancers is diagnosed with BRAF wild-type Stage IIIA melanoma — Helen H Moon, MD (32:52)
Case: A man in his late 50s with past medical history of Stage III melanoma and multiple metastatic recurrences responds to single-agent pembrolizumab — Warren S Brenner, MD (43:02)
Case: A man in his mid 70s develops metastatic recurrence of melanoma after relatlimab/nivolumab on clinical trial and pembrolizumab therapy for Stage III BRAF V600K-mutated melanoma — Priya Rudolph, MD (50:48)
Case: A woman in her mid 30s with a personal and family history of melanoma develops multiple axillary nodes with BRAF-mutated melanoma without a primary lesion — Dr Moon (58:18)

CME information and select publications

Lung Cancer | Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy Sep 08, 2023

Show notes

Featuring perspectives from Dr Corey J Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands, including the following topics:

Optimal use of front-line immune checkpoint inhibition for metastatic non-small cell lung cancer (NSCLC) (00:00)
Case: A man in his late 60s with NSCLC, no actionable mutations, PD-L1 20%, who received second-line datopotamab deruxtecan as part of a clinical trial (12:29)
Case: A man in his early 70s with metastatic NSCLC, PD-L1 30%, who received first-line chemotherapy with pembrolizumab followed by maintenance pembrolizumab and second-line ramucirumab/pembrolizumab after disease progression (29:29)
Case: A man in his mid 60s, PD-L1 60% and no actionable mutations who received first-line single-agent pembrolizumab followed by the addition of chemotherapy and chemotherapy/immunotherapy maintenance for NSCLC (40:23)
Case: A woman in her late 60s with NSCLC, PD-L1 60%, with complete response in the liver and lung to second-line tumor treating fields with atezolizumab (57:18)
Current Management of NSCLC After Disease Progression on Anti-PD-1/PD-L1-Containing Regimens — Dr Langer (1:10:48)
Potential Role of Novel Immunotherapy-Based Combination Strategies in Progressive Advanced NSCLC – Dr Reckamp (1:30:14)
TROP2 and Novel Antibody Drug Conjugates Under Evaluation in NSCLC – Dr Sands (1:53:36)
Other Promising Therapeutic Strategies for Patients with Progressive Metastatic NSCLC – Dr Leal (2:18:58)

CME information and select publications

Hepatocellular Carcinoma | The Implications of Recent Data Sets for the Management of Hepatocellular Carcinoma Sep 06, 2023

Show notes

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Daneng Li, including the following topics:

Introduction: Etiology of Hepatocellular Carcinoma (HCC) and IO Response (0:00)
First-Line Therapy for Advanced HCC — Dr Abou-Alfa (17:42)
Second- and Later-Line Therapy for Advanced HCC; Emerging Considerations for Patients with Resectable HCC — Dr Li (38:12)

CME information and select publications

Prostate Cancer | Neal D Shore, MD Sep 01, 2023

Show notes

Inside the Issue: Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer | Faculty Presentation: Treatment Intensification for Patients with Locally Advanced and Biochemically Recurrent Prostate Cancer — Neal D Shore, MD

CME information and select publications

Prostate Cancer | Inside the Issue: Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer Sep 01, 2023

Show notes

Featuring perspectives from Dr Neal D Shore and Dr Mary-Ellen Taplin, including the following topics:

Introduction (0:00)
Key Data Sets (8:18)
Faculty Survey (39:50)

CME information and select publications

Mantle Cell Lymphoma | Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma Aug 31, 2023

Show notes

Featuring perspectives from Dr Michael Wang, including the following topics:

Algorithm for observation versus initiation of therapy for newly diagnosed mantle cell lymphoma (MCL) (0:00)
First- and second-line therapy approaches for MCL (7:26)
Case: A 45-year-old woman with relapsed MCL receiving acalabrutinib who develops severe headaches (10:21)
Current role of ibrutinib in the treatment of MCL; use of single-agent venetoclax and of zanubrutinib in the treatment algorithm (14:59)
Case: A 68-year-old man presenting with an enlarged spleen, no lymphadenopathy and a white blood cell count of 300,000 is diagnosed with MCL (17:48)
Case: A 71-year-old man with multiregimen-relapsed, nodular type MCL presents with lymphadenopathy and a 3-cm tumor near the mediastinum (22:38)
Patient selection for chimeric antigen receptor T-cell therapy (25:59)
Novel and investigational therapeutic approaches for MCL (30:11)
Treatment approaches for other histological variants of MCL (39:00)

CME information and select publications

Mantle Cell Lymphoma | Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma (Companion Faculty Lecture) Aug 31, 2023

Show notes

Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics:

Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00)
Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrutinib for MCL (4:36)
Phase III TRIANGLE trial of ibrutinib combined with chemotherapy as upfront therapy for younger patients with MCL; role of autologous stem cell transplant (11:14)
Acalabrutinib and zanubrutinib for the treatment of relapsed/refractory (R/R) MCL (14:16)
Key findings from the BRUIN trial leading to the FDA approval of pirtobrutinib for R/R MCL (16:23)

CME information and select publications

Soft Tissue Sarcoma | Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series Aug 30, 2023

Show notes

Featuring perspectives from Dr Richard F Riedel, including the following topics:

Introduction: (0:00)
Case: A woman in her late 20s with multiregimen-recurrent metastatic alveolar soft part sarcoma after treatment with multiple VEGF tyrosine kinase inhibitors and a single-agent PD-1 inhibitor receives axitinib/pembrolizumab — Nam Bui, MD (4:14)
Case: A man in his mid 60s with metastatic dedifferentiated chondrosarcoma of the right femur undergoes resection and receives doxorubicin/cisplatin followed by maintenance pembrolizumab — IDH2 and TERT promoter mutations, PD-L1 2+ by IHC — Melanie B Thomas, MD (10:06)
Case: A man in his early 30s with an asymptomatic "bulge on abdomen" found to be a 6.2-cm mass receives a diagnosis via biopsy of desmoid fibromatosis. Local treatment team recommends surgery — Dr Bui (22:20)
Case: A woman in her early 40s with a history of familial adenomatous polyposis undergoes surgical excision of 3 colon cancer lesions followed by adjuvant capecitabine. On follow-up she is found to have a rapidly enlarging mass abutting the iliac and mesenteric vessels. Fine needle aspiration shows desmoid tumor — Dr Bui (29:37)
Case: A man in his mid 30s with a protruding mass on his back diagnosed as a desmoid tumor receives sorafenib followed by second-line liposomal doxorubicin — Atif M Hussein, MD, MMM (33:29)
Case: A man in his mid 50s with multiregimen-recurrent metastatic mediastinal liposarcoma receives resection, chemotherapy and eribulin — CDK4 amplification identified by next-generation sequencing (NGS) — Dr Thomas (39:31)
Case: A man in his late 60s with abdominal pain and weight loss is diagnosed with metastatic high-grade myxoid liposarcoma of the retroperitoneum — Dr Hussein (43:06)
Case: A woman in her late 50s diagnosed with Grade 2 leiomyosarcoma develops a recurrence 3 years after resection and adjuvant doxorubicin/ifosfamide — Dr Hussein (47:34)
Case: A woman in her early 60s presents to the ER with shortness of breath and is diagnosed with unresectable leiomyosarcoma of the mediastinum — Dr Bui (51:48)
Case: A man in his mid 40s diagnosed with gastrointestinal stromal tumor (GIST) receives neoadjuvant imatinib followed by resection, then adjuvant imatinib — KIT exon 9 mutation identified by NGS — Dr Bui (54:13)
Case: A man in his mid 60s with mesenteric recurrence of abdominal GIST experiences transaminitis with imatinib — microsatellite stable, no actionable mutations by NGS — Dr Thomas (58:40)

CME information and select publications

Chronic Lymphocytic Leukemia and Lymphoma | Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences Aug 29, 2023

Show notes

Featuring an interview with Dr Jeremy Abramson, including the following topics:

Choice of Bruton tyrosine kinase (BTK) inhibitor as first-line therapy for chronic lymphocytic leukemia (CLL) (0:00)
Perspectives on the use of chemoimmunotherapy versus BTK inhibitors as front-line treatment for CLL (2:31)
Chimeric antigen receptor (CAR) T-cell therapy-associated ICANS (immune effector cell-associated neurotoxicity syndrome) and infectious complications in patients with CLL (6:21)
Available data with bispecific antibodies for CLL (9:38)
Sequencing CAR T-cell therapy and pirtobrutinib for patients with previously treated CLL (11:09)
Integrating bispecific antibodies into community-based practice; strategies for mitigating associated toxicities (14:25)
CD20 versus CD19 as a therapeutic target in lymphomas (20:31)
First-line treatment selection for patients with mantle cell lymphoma (23:07)
Chemotherapy combined with nivolumab or with brentuximab vedotin as initial therapy for Hodgkin lymphoma (30:12)

CME information and select publications

Show notes

Featuring a slide presentation and related discussion from Dr Jeremy Abramson, including the following topics:

Long-term follow-up data with Bruton tyrosine kinase (BTK) inhibitors as monotherapy for chronic lymphocytic leukemia (CLL): The CLL12 and SEQUOIA trials (0:00)
Extended follow-up results with venetoclax combined with anti-CD20 antibodies or a BTK inhibitor for CLL: The CLL14, MURANO and GLOW trials (5:27)
Primary analysis of the TRANSCEND CLL 004 trial evaluating lisocabtagene maraleucel for relapsed/refractory (R/R) CLL (12:40)
Genomic evolution and resistance to pirtobrutinib in patients with covalent BTK inhibitor-pretreated CLL in the Phase I/II BRUIN study (16:24)
Chimeric antigen receptor (CAR) T-cell therapy data with axicabtagene ciloleucel and lisocabtagene maraleucel for R/R follicular lymphoma (FL) (18:24)
Bispecific antibodies as treatment for R/R FL: mosunetuzumab, epcoritamab, odronextamab and TNB-486 (22:57)
Novel treatment approaches for mantle cell lymphoma (MCL): First-line acalabrutinib/rituximab and lisocabtagene maraleucel for R/R disease (32:54)
Updated results from studies evaluating loncastuximab tesirine, such as LOTIS-2, and CAR T-cell therapy, such as TRANSFORM and ZUMA-7, for R/R diffuse large B-cell lymphoma (39:29)
Ongoing follow-up from pivotal trials of bispecific antibodies for large B-cell lymphomas (46:01)
SWOG-S1826: Results from the Phase III trial evaluating nivolumab with doxorubicin/vinblastine/dacarbazine (AVD) versus brentuximab vedotin with AVD for advanced-stage classic Hodgkin lymphoma (51:48)

CME information and select publications